Publications en collaboration avec des chercheurs de Hospital Universitario de Donostia (120)

2024

  1. Bacteria–Fungi Interactions in Multiple Sclerosis

    Microorganisms, Vol. 12, Núm. 5

  2. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  3. Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479] (Autoimmunity Reviews (2023) 22(12), (S1568997223002136), (10.1016/j.autrev.2023.103479))

    Autoimmunity Reviews

  4. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  5. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418

2023

  1. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713

  2. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  3. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  4. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  5. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  6. Early biochemical analysis of COVID-19 patients helps severity prediction

    PLoS ONE, Vol. 18, Núm. 5 May

  7. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  8. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  9. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  10. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  11. Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection

    Frontiers in Aging, Vol. 4

  12. In-depth blood immune profiling of Good syndrome patients

    Frontiers in Immunology, Vol. 14

  13. Laboratory and clinical practices in antinuclear antibody detection and related antigens: recommendations from a Spanish multicentre survey

    Immunologic Research, Vol. 71, Núm. 5, pp. 749-759

  14. Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel

    Autoimmunity Reviews, Vol. 22, Núm. 12

  15. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644